Chris Robillard
Corporate Officer/Principal bij CRINETICS PHARMACEUTICALS, INC.
Profiel
Chris Robillard is currently the Chief Business Officer at Crinetics Pharmaceuticals, Inc. He previously worked as the Vice President & Head of Business Development at Goldfinch Bio, Inc. and as the Head of Business Development & Corporate Strategy at Karyopharm Therapeutics, Inc. Mr. Robillard completed his undergraduate degree at Lehigh University and holds an MBA from Pepperdine University.
Actieve functies van Chris Robillard
| Bedrijven | Functie | Begin |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 21-03-2022 |
Eerdere bekende functies van Chris Robillard
| Bedrijven | Functie | Einde |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Corporate Officer/Principal | - |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Opleiding van Chris Robillard
| Lehigh University | Undergraduate Degree |
| Pepperdine University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Health Technology |
